NK,103.11 Application No: 10/616,448 Page 2 of 5

IN THE CLAIMS:

Please substitute the following listing of claims for the previous listing of claims.

1. (Currently amended) A method for the pulmonary administration [[of]] of a dry powder drug composition from a passive dry powder inhaler to the respiratory tract of a patient, the method comprising:


providing a dry powder drug composition comprising particles comprising a lipid matrix and <u>an active agent</u>, and the particles having a particle size of 1-30 microns, mass median aerodynamic diameter of less than 5 microns, and bulk density of less than 0.5 g/cm³;

loading the drug dry powder composition into a passive dry powder inhaler having a resistance of from 0.01 to 0.30 (cmH₂0)^{1/2}/Lmin⁻¹; and

administering the drug dry powder composition from the inhaler to the respiratory tract of a patient,

wherein the emitted dose is at least 60% for flow rates from 10 to 60 liters per minute.

- 2. (Cancelled.)
- 3. (Previously presented) A method according to claim 2 wherein the emitted dose is at least 80% for flow rates from 10 to 60 liters per minute.
- 4. (Currently amended) A method according to claim 1 wherein the fine particle fraction, which is the fraction of the particles emitted from the inhaler as determined by an Anderson Cascade Impaction or multi-stage liquid impinger, is at least 60%.



NK.103.11 Application No: 10/616,448 Page 3 of 5

5. (Currently amended) A method according to claim 1 wherein the lipid comprises a phospholipid selected from the group consisting of dipalmitoylphosphatidylcholine, disteroylphosphatidylcholine, diphosphatidylcholine, diphosphatidylcholine, diphosphatidylcholine, diphosphatidylcholine, diphosphatidylcholine, diphosphatidylcholine, diphosphatidylcholines, long-chain saturated phosphatidylghositols, long-chain saturated phosphatidylghositols.

6-10. (Cancelled.)

- 11. (Previously presented) A method according to claim 1 wherein the lung deposition is greater than 25%.
- 12. (Original) A method according to claim 1 wherein the lung deposition is greater than 30%.
- 13. (Original) A method according to claim 1 wherein the lung deposition is greater than 50%.
- 14. (Currently amended) A method according to claim 1 wherein the drug active agent is selected from the group consisting of budesonide, tobramycin sulfate, leuprolide acetate, Amphotericin B and PTH.
- 15. (Previously presented) A method according to claim 1 wherein the powder comprises hollow porous microparticles.

16-20. (Cancelled).